Literature DB >> 11978764

Identification of transcriptional targets for Six5: implication for the pathogenesis of myotonic dystrophy type 1.

Shigeru Sato1, Miwa Nakamura, Diane H Cho, Stephen J Tapscott, Hidenori Ozaki, Kiyoshi Kawakami.   

Abstract

Myotonic dystrophy 1 (DM1) is the most common inherited neuromuscular disease in adults. The disorder, characterized by myotonia, muscle wasting and weakness, cataract, insulin resistance, and mental impairment, is caused by the expansion of an unstable CTG repeat located in the 3' untranslated region of DMPK. The repeat expansion suppresses the expression of the homeobox gene SIX5. We describe here an experimental system to identify downstream transcriptional targets of mouse Six5 in order to elucidate the role of SIX5 in the pathogenesis of DM1 and development. By overexpressing a constitutively active Six5 (VP16-Six5wt) using adenovirus-mediated gene transfer in P19 cells and subsequent expression profiling using cDNA arrays, 21 genes, whose expression level increased by the treatment, were identified as potential target genes. Genes expressed in the somites, skeletal muscles, brain and meninges comprised the majority, suggesting the role of Six5 in the development and function of mesodermal tissues and brain. We provide evidence that Igfbp5 encoding a component of IGF signaling is a direct Six5-target. Moreover, the overall expression level of Igfbp5 was decreased in Six5-deficient mouse fibroblasts, and the response of human IGFBP5 to MyoD-induced muscle conversion was altered in cells of DM1 patients. Our results not only identify Six5 as an activator that directs Igfbp5 expression but also suggest that reduced SIX5 expression in DM1 might contribute to specific aspects of the DM1 phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11978764     DOI: 10.1093/hmg/11.9.1045

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

Review 1.  The sine oculis homeobox (SIX) family of transcription factors as regulators of development and disease.

Authors:  J P Kumar
Journal:  Cell Mol Life Sci       Date:  2009-02       Impact factor: 9.261

2.  Molecular interaction and synergistic activation of a promoter by Six, Eya, and Dach proteins mediated through CREB binding protein.

Authors:  Keiko Ikeda; Yoko Watanabe; Hiromi Ohto; Kiyoshi Kawakami
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

3.  Fuchs endothelial corneal dystrophy in patients with myotonic dystrophy: a case series.

Authors:  Devin Gattey; Angela Y Zhu; Anna Stagner; Mark A Terry; Albert S Jun
Journal:  Cornea       Date:  2014-01       Impact factor: 2.651

4.  MyoD reprogramming requires Six1 and Six4 homeoproteins: genome-wide cis-regulatory module analysis.

Authors:  Marc Santolini; Iori Sakakibara; Morgane Gauthier; Francesc Ribas-Aulinas; Hirotaka Takahashi; Tatsuya Sawasaki; Vincent Mouly; Jean-Paul Concordet; Pierre-Antoine Defossez; Vincent Hakim; Pascal Maire
Journal:  Nucleic Acids Res       Date:  2016-06-14       Impact factor: 16.971

Review 5.  Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1.

Authors:  Sylvia Nieuwenhuis; Kees Okkersen; Joanna Widomska; Paul Blom; Peter A C 't Hoen; Baziel van Engelen; Jeffrey C Glennon
Journal:  Front Neurol       Date:  2019-11-26       Impact factor: 4.003

6.  Six1 and Six2 of the Sine Oculis Homeobox Subfamily are Not Functionally Interchangeable in Mouse Nephron Formation.

Authors:  Jinshu Xu; Jun Li; Aarthi Ramakrishnan; Hanen Yan; Li Shen; Pin-Xian Xu
Journal:  Front Cell Dev Biol       Date:  2022-02-01

Review 7.  Core Clinical Phenotypes in Myotonic Dystrophies.

Authors:  Stephan Wenninger; Federica Montagnese; Benedikt Schoser
Journal:  Front Neurol       Date:  2018-05-02       Impact factor: 4.003

8.  Testing Proximity of Genomic Regions to Transcription Start Sites and Enhancers Complements Gene Set Enrichment Testing.

Authors:  Christopher Lee; Kai Wang; Tingting Qin; Maureen A Sartor
Journal:  Front Genet       Date:  2020-03-06       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.